ASLAN Pharmaceuticals Announces the Move of its Primary Listing to Nasdaq and Delisting From Taipei Exchange

Dr Carl Firth, Chief Executive Officer, ASLAN Pharmaceuticals, said: “Changing the company’s primary listing to Nasdaq will enhance our ability to raise capital given the greater flexibility afforded …
( read original story …)


Search your Hotel